| Name | Title | Contact Details |
|---|
For more than 235 years, Takeda has been serving society with innovative medicines, helping patients reclaim valuable moments of life from illness. Now, with new healthcare solutions from prevention to care and cure, we are determined to help even more people enjoy their lives to the fullest. Our mission is simple: we strive toward better health for patients worldwide through leading innovation in medicine. This mission: • Drives our research and development of prescription drugs • Promotes our commitment to social responsibility • Marks our growth and success At Takeda, our passion for healthcare and commitment to improving lives will enable us to make the next 230 years healthier and brighter for people around the world. Our robust product pipeline is focused on treating serious diseases and disorders, including bone and joint disorders, cardiovascular disease, central nervous system disorders, chronic kidney disease, diabetes, gastroenterology, gynecological disorders and infectious disease.
SpaLab, Inc. is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SCA Pharma is a leading FDA 503B outsourcing facility delivering the highest quality sterile admixtures and pre-filled syringes to hospitals and health systems nationwide. SCA Pharma prides itself on being the most customer- and patient-focused 503B in the industry. Known for its unwavering quality and high-touch customer service, SCA Pharma is headquartered in Little Rock, AR with a sister facility in Windsor, CT. The Windsor facility boasts more than 90,000 square feet of sterile compounding laboratory and manufacturing space while Little Rock is home to SCA Pharma`s 17,000 square foot sterile compounding facility. Both facilities meet or exceed FDA cGMP manufacturing guidelines. SCA Pharma employs more than 500 people across both facilities, as well as a team of sales representatives across the country.
CARGO Therapeutics is a biotechnology company that is developing and delivering CAR T cell therapies to cure more cancer patients. Their cell therapies focus on addressing the primary mechanisms of failure, or resistance and relapse, to the currently a...